What is he best known for?
The fields of study he is best known for:
His primary areas of investigation include Nanotechnology, Detection limit, Nanoparticle, Chromatography and Plasmon.
His Nanotechnology study integrates concerns from other disciplines, such as Raman scattering and Chirality.
His Detection limit research is multidisciplinary, relying on both Aptamer, Fluorescence, Raman spectroscopy and Biosensor.
His Nanoparticle research is multidisciplinary, incorporating elements of Chemical physics, Inorganic chemistry and Semiconductor.
He combines subjects such as Pefloxacin, Monoclonal antibody, Sarafloxacin and Analytical chemistry with his study of Chromatography.
The study incorporates disciplines such as Stereoisomerism, Surface plasmon resonance, Circular polarization and Circular dichroism in addition to Plasmon.
His most cited work include:
- Present and Future of Surface-Enhanced Raman Scattering (369 citations)
- Attomolar DNA detection with chiral nanorod assemblies (310 citations)
- Light-Controlled Self-Assembly of Semiconductor Nanoparticles into Twisted Ribbons (279 citations)
What are the main themes of his work throughout his whole career to date?
Chuanlai Xu focuses on Chromatography, Detection limit, Nanotechnology, Monoclonal antibody and Nanoparticle.
Chuanlai Xu usually deals with Chromatography and limits it to topics linked to Hapten and Bovine serum albumin.
His Detection limit research integrates issues from Immunogen, Fluorescence and Aptamer.
His Nanotechnology research focuses on Plasmon and how it connects with Circular dichroism.
The Monoclonal antibody study combines topics in areas such as Molecular biology, Antigen and Enzyme.
His Nanoparticle research includes elements of Nanoscopic scale, Biophysics and DNA.
He most often published in these fields:
- Chromatography (47.76%)
- Detection limit (40.24%)
- Nanotechnology (24.24%)
What were the highlights of his more recent work (between 2019-2021)?
- Chromatography (47.76%)
- Detection limit (40.24%)
- Monoclonal antibody (18.82%)
In recent papers he was focusing on the following fields of study:
Chuanlai Xu mostly deals with Chromatography, Detection limit, Monoclonal antibody, Nanoparticle and Nanotechnology.
His Chromatography study combines topics from a wide range of disciplines, such as Colloidal gold, Hapten and Lateral flow immunoassay.
His work carried out in the field of Detection limit brings together such families of science as Affinity constant, Lincomycin and Vitamin.
His Monoclonal antibody study combines topics in areas such as Serum samples, IC50 and Enzyme.
His biological study spans a wide range of topics, including In situ, Biophysics, Aptamer, Biosensor and Nir light.
His research brings together the fields of Raman scattering and Nanotechnology.
Between 2019 and 2021, his most popular works were:
- Present and Future of Surface-Enhanced Raman Scattering (369 citations)
- Rapid and sensitive detection of diclazuril in chicken samples using a gold nanoparticle-based lateral-flow strip. (19 citations)
- Preparing monoclonal antibodies and developing immunochromatographic strips for paraquat determination in water (19 citations)
In his most recent research, the most cited papers focused on:
Chromatography, Detection limit, Nanotechnology, Nanoparticle and Antibody are his primary areas of study.
His work on Immunochromatographic test as part of general Chromatography research is frequently linked to Sibutramine, thereby connecting diverse disciplines of science.
His Detection limit research incorporates elements of Colloidal gold, Hapten and Monoclonal antibody.
Chuanlai Xu interconnects Raman scattering, Raman spectroscopy and Circular dichroism in the investigation of issues within Nanotechnology.
His Nanoparticle research includes themes of Biophysics, Plasmon and Biosensor.
His work deals with themes such as Apoptosis and Senescence, Cell biology, which intersect with Antibody.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
